Following the preparation of the next public-private partnership – Innovative Health Initiative – health policy organisations decided to write to the Health and Research and Innovation Commissioners expressing concerns about over-influence by private partners over setting strategic priorities for the future partnership.
As highlighted in the letter published today, the health industry is taking a lead on priority setting by dominating the development of the Strategic Research and Innovation Agenda – a document that will serve as a road for public spendings. This risks further tilting the balance away from public health and public interest needs.
The evaluations of the previous health research partnerships, Innovative Medicines Initiative (IMI and IMI2) pinpointed stakeholders’ concerns about the lack of inclusiveness and transparency in the selection of research priorities and governance structures. The dominance of large groups of influence representing the health industry remains a serious problem. The evaluations warned that scientific advisory groups did not have a significant influence on shaping the strategic agenda and directions of the partnership.
Signatories urge the European Commission to address these issues by: